Fate Therapeutics reports Q2 2021 results; first patient dosed with FT819 iPSC CAR T-cell therapy

FATE THERAPEUTICS INC

2022-Q2 EPS reported -$1.07 revenue$24,552,000

Q2 2021 revenue $13.4M from collaborations; R&D expenses $48.0M; cash & investments $845.1M.
First patient treated in Phase 1 trial of FT819, first-ever iPSC-derived CAR T-cell therapy, for ALL.
FT516 interim data at ASCO: 8/11 patients (73%) objective response, 6 complete responses in B-cell lymphoma.
FT538 Phase 1 in AML: 2 patients evaluable, 1 achieved CRi; dose escalation ongoing.
Appointed Dr. Mark Plavsic as Chief Technical Officer and Dr. Yuan Xu to Board of Directors.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.